Navitoclax (ABT-263)

For research use only. Not for use in humans.

目录号：S1001

CAS No. 923564-51-6

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Navitoclax (ABT-263)发表文献272篇：

Cell, 2021, 184(25):6119-6137.e26

PubMed: 34890551 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00338-X

PubMed: 34270926 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2022, 10.1021/acsami.1c22138

PubMed: 35014784 ( click the link to review the publication )

Dev Cell, 2021, S1534-5807(21)00360-9

PubMed: 34004159 ( click the link to review the publication )

Cancer Res, 2021, 81(23):5935-5947

PubMed: 34580063 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 36(1):109334

PubMed: 34233184 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01910-6

PubMed: 34193942 ( click the link to review the publication )

Cancers (Basel), 2021, 13(16)4123

PubMed: 34439278 ( click the link to review the publication )
Cancers (Basel), 2021, 13(14)3464

PubMed: 34298678 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):406

PubMed: 33859162 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):275

PubMed: 34608124 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):741

PubMed: 34315868 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):54

PubMed: 33423045 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01441-7

PubMed: 34088988 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.MCT-21-0474-A.2021

PubMed: 34667112 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13060

PubMed: 34258881 ( click the link to review the publication )

Clin Sci (Lond), 2021, 135(15):1873-1895

PubMed: 34318888 ( click the link to review the publication )

Antioxidants (Basel), 2021, 10(6)956

PubMed: 34203664 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(4):651-666

PubMed: 33443106 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(8)3811

PubMed: 33917026 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-021-1933-7

PubMed: 34109475 ( click the link to review the publication )

BMC Geriatr, 2021, 21(1):225

PubMed: 33794800 ( click the link to review the publication )

Transl Oncol, 2021, 14(5):101048

PubMed: 33667892 ( click the link to review the publication )

Tissue Eng Regen Med, 2021, 18(5):841-850

PubMed: 34003467 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):88

PubMed: 33750370 ( click the link to review the publication )

PLoS Comput Biol, 2021, 17(2):e1008630

PubMed: 33617523 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1134

PubMed: 33602934 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1281

PubMed: 33627663 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):60

PubMed: 34040000 ( click the link to review the publication )
Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Med Chem, 2020, 63(22):13733-13744

PubMed: 33197310 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):130

PubMed: 33239070 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):854

PubMed: 33056980 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(11)E1143

PubMed: 33218059 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0586.2020

PubMed: 33288732 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Front Pharmacol, 2020, 11:615505

PubMed: 33519480 ( click the link to review the publication )
Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, S0360-3016(20)34731-3

PubMed: 33385497 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Anat Cell Biol, 2020, 53(4):471-480

PubMed: 33361545 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Trop Life Sci Res, 2020, 31(3):1-13

PubMed: 33214852 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )
Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )
Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Oncogene, 2018, 37(22):2936-2952

PubMed: 29520102 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):445

PubMed: 29670075 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Mol Oncol, 2018, 12(3):287-304

PubMed: 29063678 ( click the link to review the publication )
Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Sci Rep, 2018, 8(1):16822

PubMed: 30429524 ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(2):382-387

PubMed: 28028240 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(4):693-703

PubMed: 28401730 ( click the link to review the publication )
Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Tumour Biol, 2017, 39(5):1010428317699120

PubMed: 28459212 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )
Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82013-82027

PubMed: 27852038 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2034

PubMed: 26720343 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )
Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1028

PubMed: 24481442 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )
PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10237-50

PubMed: 25296978 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

J Neurosci, 2013, 33(12):5195-207

PubMed: 23516285 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )
Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4518-26

PubMed: 21546570 ( click the link to review the publication )

PLoS One, 2011, 6(8):e21980

PubMed: 21829603 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
FL5.12	NILxR2FEgXSxdH;4bYNqfHliYYPzZZk>	MnjBNlQhcA>?	M2mw[WVEPTBiPTCwMlAxPDJizszN	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG4PFIoRjF6OESxPFgzRC:jPh?=
FL5.12	NV2xU2RTS3m2b4TvfIlkcXS7IHHzd4F6	M3LHXVI1KGh?	MXTFR\|UxKD1iMD6wNFU6KM7:TR?=	NW\aTJA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
RS4:11	NXLVcGU5SXCxcITvd4l{KGG\|c3H5	NXH0VWVnPiCq	NEL2TY5GSzVyIE2gNE4xOTRizszN	NUD6dldbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
FDC-P1	M4DofmJEVC1{IHnubIljcXSrb36gZZN{[Xl?	MWOyOEBp	M364OWlEPTBiPTCwMlAyPSEQvF2=	NV;yVGkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
NCI-H1963	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=	MnH5OEBl[Xm\|	MX;JR\|UxKD1iMD6wNlY3KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2OEK5PEc,OjN2NEiyPVg9N2F-
NCI-H187	MkTRR5l1d3SxeHnjbZR6KGG\|c3H5	NIXOSoY1KGSjeYO=	Mnu3TWM2OCB;IECuNFM5PCEQvF2=	NGf4cmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H1417	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=	M4nXT\|Qh\GG7cx?=	MWrJR\|UxKD1iMD6wOVQzKM7:TR?=	NVTCNoFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFgzQThpPkKzOFQ5Ojl6PD;hQi=>
FDC-P1	NUTWTpVXSkOOLYjMJIlvcGmkaYTpc44h[XO\|YYm=	NXXlS\|dXOjRiaB?=	MX7JR\|UxKD1iMD6wOkDPxE1?	NWjTbm81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
NCI-H146	NWTVXFdVS3m2b4TvfIlkcXS7IHHzd4F6	NEe3bY41QCCq	NUn5XlRkTUN3MDC9JFAvODh4NzFOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh2MUi4Nkc,OTh6NEG4PFI9N2F-
RS4:11	MojQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MmLmSWM2OCB;IECuNVEzKM7:TR?=	MmnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFcoRjJ6OUK2NlQ4RC:jPh?=
MOLT4	NFLieWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MYDFR\|UxKD1iMD6zNFMh\|ryP	NUXPOJBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlYzPDdpPkK4PVI3OjR5PD;hQi=>
EoL-1-cell	NXvqe2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV7JR\|UxRTBwMEC2Olkh\|ryP	MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MV-4-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HBVGlEPTB;MD6wNVU5PiEQvF2=	MkPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NKM-1	M1zlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWrJR\|UxRTBwMEG2PVkh\|ryP	NF3IVnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ML-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmTJTWM2OD1yLkCxPVg{KM7:TR?=	MoLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BV-173	M1fkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlTUTWM2OD1yLkCyN\|E1KM7:TR?=	NV3SeZBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RS4-11	M4XUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnG1TWM2OD1yLkCyOVg4KM7:TR?=	NWHBXGZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HL-60	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1LkOmlEPTB;MD6wNlkxQCEQvF2=	NX;ZSXVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KY821	M4Hkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlr6TWM2OD1yLkCyPVc2KM7:TR?=	MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ECC10	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkTTTWM2OD1yLkCzO\|kzKM7:TR?=	NWTDTVd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H720	NUTCNHlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVnJfHhLUUN3ME2wMlA1ODFzIN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
QIMR-WIL	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1nX[2lEPTB;MD6wOFI5PyEQvF2=	M13oVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KG-1	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXTOHBKSzVyPUCuNFQ1QDZizszN	MkftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGW	M{jvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4LK[2lEPTB;MD6wOFY{OyEQvF2=	NETCb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ATN-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjlVG1KSzVyPUCuNFQ4OzNizszN	MmO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RH-18	NIjIcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrEb5NKSzVyPUCuNFYxPDhizszN	NXrRUJJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-18	M2TLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jXe2lEPTB;MD6wOlg1OSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB17	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NU\RT4ZlUUN3ME2wMlA4OTJ2IN88US=>	M{\LXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-NEP-1	M3vqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYHpeHExUUN3ME2wMlA4OjF\|IN88US=>	NVvkXop2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFy4TFZKSzVyPUCuNFc4PzhizszN	NHLkfpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KARPAS-45	M1rxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIjwWmZKSzVyPUCuNFc5OTVizszN	NFfTXGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mlj5TWM2OD1yLkC4NFU{KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB13	NELxeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3PrbGlEPTB;MD6wPFIxOyEQvF2=	NWnKXGR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H209	M4Oxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4PjNWlEPTB;MD6wPFcxPCEQvF2=	Mn:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1092	NH\4NJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3afHFKSzVyPUCuNVAzPzVizszN	M3nLfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NH-12	M4jTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MULJR\|UxRTBwMUC3OFQh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
697	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfO[lZKSzVyPUCuNVA5OzlizszN	M3zKNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KE-37	NUOyR41ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MofVTWM2OD1yLkGxN\|ch\|ryP	NU\5b2hQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-4	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LxT2lEPTB;MD6xOVE3QSEQvF2=	NY\hPHdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CHP-134	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{ezXWlEPTB;MD6xOlMxPiEQvF2=	MkDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
D-283MED	M2DN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEfQSWNKSzVyPUCuNVc3QDZizszN	M4nsc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-135	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{nlXGlEPTB;MD6xPFU2OiEQvF2=	M{TJWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-134-A	NYnFeW43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVzJR\|UxRTBwMUi2O\|Eh\|ryP	Mlz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EM-2	M3vOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVXwUop4UUN3ME2wMlE6QTF6IN88US=>	M{DVdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-139	NWLtSog4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX7oe5JFUUN3ME2wMlIxPDl6IN88US=>	M1e4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ALL-PO	NGjjOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVzLdnF6UUN3ME2wMlIyQTh6IN88US=>	M4TrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB12	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXkV2JKSzVyPUCuNlMyOTVizszN	NXjod\|B{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KP-N-YN	NX;NToFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3m3XWlEPTB;MD6yN\|U4OyEQvF2=	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BEN	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1rXbGlEPTB;MD6yN\|k3QCEQvF2=	NGHxbnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC1569	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MULJR\|UxRTBwMkWxNFYh\|ryP	NGLvWIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuO9	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV\HS5hUUUN3ME2wMlI3PzF3IN88US=>	NGXjVmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
WM-115	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYnJR\|UxRTBwMke3N\|gh\|ryP	NXvi[FhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CCRF-CEM	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnYfHlKSzVyPUCuN\|M2OjlizszN	M{LrbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
IST-SL1	NHfPfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYrJR\|UxRTBwM{WzOFMh\|ryP	M1vHOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BE-13	M1PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYHSZ\|N1UUN3ME2wMlM3PDV7IN88US=>	NXTMOGF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COR-L88	NFzTSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGqyc5JKSzVyPUCuN\|Y2PCEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DOHH-2	NVXCcmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHnlZVRKSzVyPUCuOFExOjNizszN	M{XYU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A704	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDLfY9KSzVyPUCuOFI3PyEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KNS-81-FD	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2P6S2lEPTB;MD60OFAyPyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RPMI-8226	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIriWpNKSzVyPUCuOFU3PTJizszN	NXq3UWdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TGBC24TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYXJR\|UxRTBwNEW3O\|gh\|ryP	M4fEU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1304	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVfJR\|UxRTBwNE[xOVch\|ryP	MnjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MOLT-13	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlrWTWM2OD1yLkS2OlE{KM7:TR?=	Mm\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-22	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWfJR\|UxRTBwNE[2O\|Eh\|ryP	NGS1Opc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MS-1	NF;2UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmXxTWM2OD1yLkS2PVM{KM7:TR?=	M{DlUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RMG-I	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3H0V2lEPTB;MD60PVQ3PCEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFq1dnZKSzVyPUCuOVAxOTlizszN	NGfqSoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1048	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1roZmlEPTB;MD61NFk2OyEQvF2=	NYXDOHUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1417	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGizWlVKSzVyPUCuOVU1OzhizszN	NVK1e4NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DB	NUmwblI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmLkTWM2OD1yLkW3NFgh\|ryP	NYO5bVltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MEG-01	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLm[nVKSzVyPUCuOVg{OiEQvF2=	MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-13	NGnFXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVLJR\|UxRTBwNUizOFEh\|ryP	M{KxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LAMA-84	NEjNfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rKWmlEPTB;MD61PVIxPyEQvF2=	NXvH[VhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5	M3\ZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUfJR\|UxRTBwNkC4NFgh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MOLT-16	M3jwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXyT2ROUUN3ME2wMlY2OjZ2IN88US=>	Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DU-4475	NEHxXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\sVlExUUN3ME2wMlY2PDJ5IN88US=>	Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HAL-01	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUDL[WJLUUN3ME2wMlczPTR7IN88US=>	NI\NdHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RD	NH\HXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXW4WGtLUUN3ME2wMlc2QDl7IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OAW-28	M1za[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWXJR\|UxRTBwN{izO{DPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC38	NEHMOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTYTWM2OD1yLkiwNVkh\|ryP	NXXic493RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NMC-G1	NGDyUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkHoTWM2OD1yLkixNVIyKM7:TR?=	M4ixTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-16	MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInVSXdKSzVyPUCuPFE{OjhizszN	Mm[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DU-145	NXjMV\|E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{PnT2lEPTB;MD64PVkzOyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HPAF-II	NHOxPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn\KTWM2OD1yLkmyOlI5KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A427	M3vEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEPUVJZKSzVyPUCuPVMxOjJizszN	NVvlZWh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PA-1	NGDScWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIXPcYZKSzVyPUCuPVU3PDJizszN	NIHPPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OAW-42	NWPhbZlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGLKbFhKSzVyPUCuPVYyPDZizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
L-428	NI\xRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUGycldxUUN3ME2xMlAyOjVizszN	Mnu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-824	NFG4[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGXIdGhKSzVyPUGuNFE4ODhizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
P30-OHK	NFnsSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorKTWM2OD1zLkC0Olg5KM7:TR?=	Mni0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2170	M4rjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX3GXW8zUUN3ME2xMlA3OjNizszN	NEjMV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC2998	NETYbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUHJR\|UxRTFwMEexN\|Uh\|ryP	NEexd2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB14	NHPnb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVrrbJNUUUN3ME2xMlE{PzR6IN88US=>	M4jqfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TGBC1TKB	NIfFOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUHjXnl6UUN3ME2xMlE1OTV{IN88US=>	NUf5enBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KP-N-YS	NUjZeo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml\LTWM2OD1zLkG2NlM3KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAL-120	NEXSU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoHJTWM2OD1zLkG2OFI6KM7:TR?=	NXf4dIdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SBC-1	M1jPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlnGTWM2OD1zLkG5NFU{KM7:TR?=	M{fkTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
C32	NEj0eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXnJR\|UxRTFwMUmwPFgh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC2157	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1\iVGlEPTB;MT6xPVQ6PCEQvF2=	NE[0NVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COLO-792	NYL0TGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlTVTWM2OD1zLkKwNFcyKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES7	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUfJR\|UxRTFwMke5OVEh\|ryP	MmrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HEL	NHLJbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkDqTWM2OD1zLkOxNFI6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES4	NFHOcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGr2VnFKSzVyPUGuN\|Q6QThizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYTxeolnUUN3ME2xMlM3PTV3IN88US=>	Mme5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-415	NWPCS2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn34TWM2OD1zLkO4PFUh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2342	M1H6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXnJR\|UxRTFwNECyOlkh\|ryP	NVzoZYNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB69	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVPPe2xWUUN3ME2xMlQ3OjdzIN88US=>	NIj4ZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-247MG	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVLkT411UUN3ME2xMlUyOTJ{IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SCC-4	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlS5TWM2OD1zLkW5PFg4KM7:TR?=	NH7NUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuH-7	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnziTWM2OD1zLk[3Nlk{KM7:TR?=	M2nvPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A388	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWLTZ\|lmUUN3ME2xMlY5PzJ2IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Calu-3	NVzHR5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEXTNZlKSzVyPUGuO\|A3QTdizszN	NFHlPZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1648	M1HEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MonrTWM2OD1zLkexOFE5KM7:TR?=	NV7SRlFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2052	NUPXTWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MknUTWM2OD1zLkeyNlAyKM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXPJR\|UxRTFwN{O2OVYh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DEL	NHvXOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH[4T3VKSzVyPUGuO\|Q3QTJizszN	NXnqb5V1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SNU-423	NXzrUmFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2G5PGlEPTB;MT63PFE2PyEQvF2=	NEDabmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COR-L23	NGDOdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MknVTWM2OD1zLke5PFc1KM7:TR?=	NHLXbpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OMC-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{PqNWlEPTB;MT64OlAyPiEQvF2=	NH;NO2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-11	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFX4TWtKSzVyPUGuPVU3PTdizszN	MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HSC-3	M{PDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXPaTo06UUN3ME2xMlk3OzZ3IN88US=>	NUXLWGYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MLMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rtTmlEPTB;MT65OlY4PyEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RCM-1	M2TPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXm1V21rUUN3ME2yMlAxOzl7IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MFE-280	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHjs[mhKSzVyPUKuNFI5PDhizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES8	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml3QTWM2OD1{LkK1OFcyKM7:TR?=	M2e2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TE-11	NX7VU4ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfuS\|lKSzVyPUKuNlk1PzNizszN	Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HuO-3N1	NWTGSIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MniyTWM2OD1{LkS4O\|gh\|ryP	M2fZeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MHH-NB-11	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInhU2dKSzVyPUKuOVEyPThizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TGBC11TKB	M13wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHTwUG5KSzVyPUKuOVc3QDFizszN	M1mzSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HOP-92	M3rNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzMUFdKSzVyPUKuOVg4PDNizszN	MmTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
IGR-1	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXnvNZZOUUN3ME2yMlYzODN3IN88US=>	NHLlNXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GOTO	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEHZcIRKSzVyPUKuOlU{PzdizszN	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1650	MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF:xSGdKSzVyPUKuO\|IzOTVizszN	NYO4eVlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1581	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXjJR\|UxRTJwN{m2PFEh\|ryP	NIjNXIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2405	NI[xSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIfOTlVKSzVyPUKuPFI4QDJizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
U-118-MG	NYO5XZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTHTWM2OD1{Lkm2OFkyKM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DoTc2-4510	NHzTNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mkn5TWM2OD1\|LkCxOFE4KM7:TR?=	MlvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H596	NWHrUYZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX3JR\|UxRTNwMES5PVch\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MPP-89	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkPSTWM2OD1\|LkC1OlY3KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GCIY	MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4fYemlEPTB;Mz6yNFQ6OSEQvF2=	NFfMSZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW626	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MofDTWM2OD1\|LkK0OVQ{KM7:TR?=	NX3XWJJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OCI-AML2	M1j0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX;JR\|UxRTNwM{GyO\|Ih\|ryP	MnruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NBsusSR	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY\JR\|UxRTNwM{S5N\|gh\|ryP	NV7kXWp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AN3-CA	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;zeW1KSzVyPUOuOFQzOzhizszN	M3LsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EFM-19	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUHJR\|UxRTNwNEizN\|kh\|ryP	MoP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RVH-421	NGjkPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorLTWM2OD1\|LkW2PFc4KM7:TR?=	NVzxepUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
5637	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnIWGFKSzVyPUOuOlEyODNizszN	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
PANC-08-13	NFy2V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoC3TWM2OD1\|Lk[zOFczKM7:TR?=	MkHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
H9	M4LuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXrJR\|UxRTNwNkexOFQh\|ryP	NWnFXm91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KARPAS-299	NV3YS3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{nLc2lEPTB;Mz62O\|M3OSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TE-5	NYPRVFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYKxPGkzUUN3ME2zMlcxPzB7IN88US=>	M2rIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NOS-1	NW\Vdod2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYXL[5RjUUN3ME2zMlc6QDN2IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HH	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX7ydIh7UUN3ME2zMlg{QDZ6IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
769-P	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7KOol{UUN3ME2zMlg6PTFizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CHP-212	NXLVeVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml\vTWM2OD1\|LkmyOVQ6KM7:TR?=	MmLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H82	M2Tzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXPJR\|UxRTNwOUW5N\|Yh\|ryP	MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Mo-T	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NY[wdWtKUUN3ME20MlA1OzF{IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BB65-RCC	M3;3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4jLdGlEPTB;ND6wOFM6QSEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1990	NYexZ2RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIKzV2lKSzVyPUSuNFU6ODhizszN	NFS3V2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LK-2	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXLRRmFYUUN3ME20MlEyOjl\|IN88US=>	NU\UeWM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES5	NXLtUI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWLJR\|UxRTRwMUO5PFUh\|ryP	NWDybW1RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
JVM-3	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVzJR\|UxRTRwMUiyNlIh\|ryP	M{HwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RPMI-7951	NUK3WVhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTsS5dKSzVyPUSuNlI1OTNizszN	NYnOZnFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Calu-6	NUHGfGVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1HEdmlEPTB;ND6yO\|g5OSEQvF2=	NGXBOmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LC-2-ad	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX;JR\|UxRTRwMkm1Olgh\|ryP	M4P0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW954	NWfkbYpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDNTWM2OD12LkK5OlYh\|ryP	NH7EVog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
H-EMC-SS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlHPTWM2OD12LkOxPFMyKM7:TR?=	NVXacG16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES3	M1PVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3rLXWlEPTB;ND6zOVQ1OSEQvF2=	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
no-11	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn3ITWM2OD12LkO1OVU1KM7:TR?=	NH;aS\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LAN-6	NWLRPVh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zLNGlEPTB;ND60OVE5QSEQvF2=	NGiyXFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
FTC-133	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfSeFZKUUN3ME20MlU{QTVizszN	NXzDXnA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
8505C	M4K5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{\5T2lEPTB;ND61OFI{KM7:TR?=	M{XHZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW620	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYXueXVEUUN3ME20MlU4ODV5IN88US=>	NYTkTYcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BCPAP	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV;JR\|UxRTRwNkO0PFEh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-LU-1	NXvDboR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHrVOZhKSzVyPUSuOlYxQDlizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1623	M4TkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWSyZ5JYUUN3ME20MlcxOjJ6IN88US=>	NEi3SYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
C2BBe1	NUTtVW42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXfJR\|UxRTRwN{SwNFgh\|ryP	NYXBcVlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GP5d	NW\ZWpVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIf2ZWRKSzVyPUSuO\|g{QDhizszN	NUTmcJp6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB6	NXn2cWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTRwOE[yNFQh\|ryP	NGPOe5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MDA-MB-157	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYn1c3ZtUUN3ME20Mlg5PzZizszN	NXXxWWVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
UMC-11	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHWSYVMUUN3ME20Mlg5QTZ2IN88US=>	MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC1419	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnHSHN7UUN3ME20MlkxODZ\|IN88US=>	NICzNVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2029	NUe4d3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGX0eZlKSzVyPUSuPVQyQDVizszN	MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LXF-289	NXmzO4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1T4RmlEPTB;NT6wN\|cyQSEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KINGS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MofUTWM2OD13LkC3O\|Q1KM7:TR?=	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU\GU4loUUN3ME21MlI{QTZ7IN88US=>	M4PPNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ESS-1	NFj3e45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3fvVmlEPTB;NT6yOVU6PyEQvF2=	NYT1dmhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GI-1	NXHJcWRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3HMUWlEPTB;NT6yO\|kzPiEQvF2=	NIS4RpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-2650	NFTwfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFPlOIxKSzVyPUWuN\|YyPiEQvF2=	M3jGdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
IA-LM	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1LnWGlEPTB;NT6zPVg4OSEQvF2=	M{fNe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KP-4	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHr4bXRKSzVyPUWuOFY{OzRizszN	MoLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
G-402	NUj3WpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUDJR\|UxRTVwNUG4OlUh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OS-RC-2	M4qyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPyfHR3UUN3ME21MlUzPjB2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1155	NEOwbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2fYbmlEPTB;NT61OFk2PSEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OE19	NV7OdYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmnMTWM2OD13Lk[4OlI1KM7:TR?=	M{jVPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
U-2-OS	NYDxV5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYKxdFBPUUN3ME21Mlg6ODF\|IN88US=>	NEXV[I89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SCC-15	NV3vc45UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{PQU2lEPTB;NT65N\|Y3OiEQvF2=	NFPjTVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H630	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVfDNW42UUN3ME21Mlk6PDB2IN88US=>	NVnBOIVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PFSK-1	M4q3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LhdmlEPTB;Nj6wOVI2QSEQvF2=	MlP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1770	M{\TZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV\JR\|UxRTZwMkC4O\|Qh\|ryP	MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NH;uUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX7pfG16UUN3ME22MlQzQTF3IN88US=>	M37UOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB1047-RCC	Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4fvWGlEPTB;Nj60O\|YzPSEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H446	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4PudGlEPTB;Nj62NlkzPSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW780	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NICyNIJKSzVyPU[uO\|AyQDVizszN	NF\6eG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NEC8	M13VRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\CNmlEPTB;Nj63OlY{KM7:TR?=	M2XYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NOMO-1	NYfZOohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH\GN5VKSzVyPU[uO\|gyOTFizszN	NH[yOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COLO-668	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\4bIFKSzVyPU[uPFQ{QDdizszN	M33YWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MC116	NIDZeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWf3VXljUUN3ME22Mlk{QDl5IN88US=>	NXPL[pJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1937	NGLVcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3HlVWlEPTB;Nj65PVI2OSEQvF2=	NVr1XGl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-N87	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXnlWoxDUUN3ME23MlE6Ojl\|IN88US=>	MkW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	NYCzPGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\0WGZKSzVyPUeuNlI4OzhizszN	M2r5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1806	M3G4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFrlc\|hKSzVyPUeuNlYxPDRizszN	NHKwfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OVCAR-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkD6TWM2OD15LkOzNFM5KM7:TR?=	M1znN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NUGC-3	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{fQS2lEPTB;Nz6zPVY6PCEQvF2=	MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1783	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nRcGlEPTB;Nz60N\|E4PSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GCT	M{XZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX64UlJpUUN3ME23MlU3QTB4IN88US=>	NUnWNlJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2126	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1rPSmlEPTB;Nz63N\|YzPSEQvF2=	M3;LVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MEL-HO	NXz5XnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXLLe\|QyUUN3ME23Mlc4ODV2IN88US=>	NELRU5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAPAN-1	M{\GbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHrieFdKSzVyPUeuO\|c{PTdizszN	NYntNpZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW756	NFiwb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGW5UXlKSzVyPUeuO\|g{OzNizszN	MmSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	M{L5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXX5OZUyUUN3ME23MlgyQDl{IN88US=>	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCE-T	NIroR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXLJR\|UxRTdwOEe3PFMh\|ryP	NYD6UVk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Ca-Ski	NUTBZ2c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4PLU2lEPTB;Nz65PVM5OyEQvF2=	NEnOb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COLO-684	M1TJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDY[lUyUUN3ME24MlAyQDF6IN88US=>	M{XaXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-70	NULUN3pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnrUTWM2OD16LkC3O\|I6KM7:TR?=	Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TI-73	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVexNndvUUN3ME24MlI2QDVzIN88US=>	NF7pR2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BT-20	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvGTWM2OD16LkK2NFUzKM7:TR?=	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MHH-ES-1	NUPSblhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUHJR\|UxRThwNUG4N\|Qh\|ryP	NXHmOpg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-12	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG\re5lKSzVyPUiuOVk6OzFizszN	Mk\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
YH-13	NYjC[\|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XBcGlEPTB;OD62NVAxQCEQvF2=	NUjPemYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SF126	NFTueGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIf3VJpKSzVyPUiuPFM5PjVizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
J82	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVGyV3dHUUN3ME24MlkxODN6IN88US=>	NVzFdIdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RCC10RGB	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M32wVGlEPTB;OD65PVU3OSEQvF2=	M{fVW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-UT-1	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoH4TWM2OD17LkC0PVQ2KM7:TR?=	NID5fnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LB2241-RCC	M3;3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHMTWM2OD17LkG5NVM4KM7:TR?=	M4DpVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB996-RCC	NG\GTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlzUTWM2OD17LkG5PFkh\|ryP	MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EPLC-272H	NH24TIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fabmlEPTB;OT6zO\|Y2PyEQvF2=	M4H5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CTV-1	NU\BNoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrMflZKSzVyPUmuOVY2OzJizszN	NVPkSWZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HSC-2	M4LZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUfJR\|UxRTlwNUe1OUDPxE1?	M17W[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-MEL-28	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTBRYVTUUN3ME25MlYyQDl\|IN88US=>	NXvlU2FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MMAC-SF	M4PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXu[pNKSzVyPUmuOlg4PSEQvF2=	MkHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CP50-MEL-B	NXzNbpNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHRN45KSzVyPUmuO\|U4QDJizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HT-1080	NF3SU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVjJR\|UxRTlwN{e3N\|kh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HEC-1	MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1mwXWlEPTB;MUCuN\|M2OiEQvF2=	M{TZV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AGS	M{Dwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDXSXMyUUN3ME2xNE4{PzRizszN	M3\r[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GAMG	M4\YPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrITWM2OD1zMD61NVYzKM7:TR?=	NHr1bo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW48	NWexflBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\CfGtKSzVyPUGwMlUyQDlizszN	NFLWcJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
U031	NYjOO2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGjPTVZKSzVyPUGwMlU6ODhizszN	M3jncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OVCAR-5	M1i5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7q[2VKSzVyPUGwMlY1OjlizszN	NIr1SpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SF295	NGf2RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYPJR\|UxRTFyLk[3NFQh\|ryP	M3ryXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BHT-101	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzWTWM2OD1zMD63NVc4KM7:TR?=	NWqzOHNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	NWPCfW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;WcWlEPTB;MUGuN\|IxOSEQvF2=	NFPrUpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ACHN	NGD6bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVzkPWllUUN3ME2xNU41OjFzIN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H526	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXq2bZA4UUN3ME2xNU42ODR\|IN88US=>	NVP3R2ZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MN-60	NXjoe3ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHy[GFpUUN3ME2xNU42OzlizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2291	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY\JR\|UxRTFzLkW0OlYh\|ryP	NY\PUXY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-25	M{XDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4nwRWlEPTB;MUGuO\|U2PiEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-2	NXHaW4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV3JcXY{UUN3ME2xNU44PjN5IN88US=>	MlL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SN12C	NVvW[lQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFzVWnpKSzVyPUGxMlk{PTVizszN	M3vIOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H69	M2\GV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIG0O3JKSzVyPUGyMlQzOzRizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ME-180	M4PrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrWTWM2OD1zMj63NFU1KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MC-IXC	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;McWlEPTB;MUKuO\|UyQCEQvF2=	M2jHelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2347	NHP1[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2jsW2lEPTB;MUKuO\|YyPCEQvF2=	NUK2ZlVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
M059J	NX3OTJRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjEe5RXUUN3ME2xNk44PzJ5IN88US=>	M3\DeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A2058	M{jhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWfJR\|UxRTF{Lki2PFEh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NF\PSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NITYSJBKSzVyPUGyMlg4QDVizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ca9-22	M{XtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTF{Lkm0OVEh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KNS-42	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoLvTWM2OD1zMj65PVg1KM7:TR?=	MkPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LoVo	NG\CdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2r2XmlEPTB;MUOuNlMyOyEQvF2=	NWfVXVd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AM-38	M1nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4K0ZmlEPTB;MUOuNlU3PiEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB5	NFuxcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGi0N5dKSzVyPUGzMlM4PTJizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
L-363	NILncpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFHNVmlKSzVyPUGzMlQxOzNizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-30	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3PIcWlEPTB;MUSuNFY1PSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1563	M2n2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFSyZYtKSzVyPUG0MlYxOzlizszN	M4f5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2228	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFG4T29KSzVyPUG0MlYxPzdizszN	NYL1UZI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MFM-223	NE\Y[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTF3LkG4NVMh\|ryP	M{S4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB831-BLC	M1Lr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1vVV2lEPTB;MUWuNlc3PyEQvF2=	Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW872	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NI\kTIpKSzVyPUG1MlMxQDZizszN	NEPh[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H522	NYDBRY9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFTEXWNKSzVyPUG1MlM{ODZizszN	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-1	NU\IZlIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2DPRmlEPTB;MUWuOVQ3OiEQvF2=	M4XQfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlToTWM2OD1zNT61PVQzKM7:TR?=	NWPQUXN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW837	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1TJdGlEPTB;MUWuO\|g1PyEQvF2=	NUfKPIs3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-9	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWrZfJdIUUN3ME2xOU45OTF2IN88US=>	Ml3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MKN7	M2m4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWfJR\|UxRTF3Lkm3N\|Ih\|ryP	M4fkelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-410	NHH1[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXfJR\|UxRTF4LkW5NUDPxE1?	Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnXCTWM2OD1zNj62NVE3KM7:TR?=	NUKx[Yo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COR-L105	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWfJR\|UxRTF4Lk[1Nlgh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LB2518-MEL	NH\hXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWPOcmx5UUN3ME2xOk45Ozh7IN88US=>	M{PHUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OVCAR-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIHj[IRKSzVyPUG2Mlg5PjJizszN	MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TK10	NXy0[Xh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUC3XlR3UUN3ME2xOk46PDd\|IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KNS-62	NUjEOox7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2XDNGlEPTB;MU[uPVc4PyEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RPMI-8866	NIjQVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW\XTmpYUUN3ME2xO{4yPzN{IN88US=>	M2jWbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HuP-T4	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPqelVVUUN3ME2xO{4zPDl3IN88US=>	MonxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	M4XhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYXHTVIzUUN3ME2xO{42OjF7IN88US=>	NHLEUnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T-24	NWPONlA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{XaeWlEPTB;MUeuOVM1PyEQvF2=	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HT-3	NGr3doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\vdpFKSzVyPUG3MlU6OTRizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KS-1	NIXrUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXu0VGo{UUN3ME2xO{43PzNizszN	NVvjVZo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1792	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mme1TWM2OD1zNz63PVgh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ABC-1	NFXvVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2WzRmlEPTB;MUeuPFE1OSEQvF2=	MojjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BPH-1	NI\BSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWroe2kyUUN3ME2xPE4yPjh3IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A431	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnfsTWM2OD1zOD60NVI4KM7:TR?=	NFzvN289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T98G	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEK2dYhKSzVyPUG4MlUyPTdizszN	NVHlVZVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BHY	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWXv[\|J[UUN3ME2xPE45PjlizszN	NVzMfJVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Capan-2	M2XPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVrqUolIUUN3ME2xPE46ODd6IN88US=>	M3m1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MDA-MB-175-VII	NVK5V2Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnrzTWM2OD1zOD65NlA6KM7:TR?=	M17md\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CAL-27	M4LVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7pdnBKSzVyPUG5MlA1QDdizszN	NU\5ZnFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AsPC-1	NUG3cYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLDW5pyUUN3ME2xPU45PjV5IN88US=>	Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KU812	M1L2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NI\0OZNKSzVyPUG5Mlk2PzNizszN	MkD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H441	NV;rRXFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGTlXmFKSzVyPUKwMlAxOSEQvF2=	MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Mewo	NHPLSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGS5NodKSzVyPUKwMlEzQDhizszN	MlTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRTJyLkG0O\|ch\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H727	M1XG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUCyPHRGUUN3ME2yNE4zPzB2IN88US=>	NW\oTW9TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EKVX	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoPmTWM2OD1{MD62NFYh\|ryP	NG\TR4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RT-112	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3T0VWlEPTB;MkCuOlEzOiEQvF2=	NF;oRmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAMA-1	NUTFTXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWLJR\|UxRTJyLkm4NFMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW900	M2XQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{jGcmlEPTB;MkGuNFE1QSEQvF2=	M1rnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H23	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV[zUmxbUUN3ME2yNU4yOjd5IN88US=>	NH\kOIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-PN-DW	Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWjGVG1iUUN3ME2yNU4yPjR7IN88US=>	NWLRNFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BB30-HNC	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUjaNHVFUUN3ME2yNU4zPzR3IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
VM-CUB-1	NVq5XoZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXTRe4Z{UUN3ME2yNU4{PTN4IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
IST-MEL1	M3njcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn3uTWM2OD1{MT6zOlkzKM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CTB-1	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfWTWM2OD1{MT60O\|U2KM7:TR?=	NFT5e4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LCLC-103H	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PiUmlEPTB;MkKuNVU5OiEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
PANC-03-27	NFTxXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWHPc2x7UUN3ME2yNk42OTZ7IN88US=>	NIDDN4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HTC-C3	NGrHdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{jRTmlEPTB;MkKuOVU2PSEQvF2=	NFXlboM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-8	NYexOFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWT4XFUzUUN3ME2yN{4zPTZ3IN88US=>	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H292	NVvnOGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnruTWM2OD1{NT6zOVM3KM7:TR?=	NXnafG15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COLO-680N	MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF[0dItKSzVyPUK1MlY{OjlizszN	NH;QNlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KYSE-520	NVO2NWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWPJR\|UxRTJ3Lk[0OEDPxE1?	M3qyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB10	M4DOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfxSWZSUUN3ME2yOk4{OTF5IN88US=>	NXrBOHRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H661	NV\Ib4tyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3fuO2lEPTB;Mk[uOFcyOyEQvF2=	MkXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
GMS-10	NFPwbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLlNpdKSzVyPUK2Mlg3OzhizszN	NGL5S5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2122	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1L5V2lEPTB;Mk[uPVk6QCEQvF2=	NFX0SWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OVCAR-8	NUPyPZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGi2XHhKSzVyPUK3MlA3OzhizszN	NVrWNIljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DJM-1	NYThUGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfocHhKSzVyPUK3MlE1PTRizszN	NIjqOGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
UACC-893	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2Pm[2lEPTB;MkeuPVg4QCEQvF2=	NELYXpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
C8166	NWfUWHBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoW0TWM2OD1{OD62PVM5KM7:TR?=	MnPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1693	NWHU[HptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUOyeo9WUUN3ME2yPE43QTd3IN88US=>	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TYK-nu	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVLJR\|UxRTNyLkCzOFUh\|ryP	NE\oeGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW1710	M4LuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXXJR\|UxRTNyLkGyOkDPxE1?	NEHM[4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A375	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfBO\|d{UUN3ME2zNE4{OjR\|IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HMV-II	NUP1WoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4TNS2lEPTB;M{GuN\|U6OiEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2087	M2rBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXXKS4pPUUN3ME2zNU43OzV{IN88US=>	M4q5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CAL-54	NEPwUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHHEN5BKSzVyPUOxMlczPDFizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC70	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzYN2tKSzVyPUOyMlE{QDdizszN	M1v0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ES1	NH2xb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXHJR\|UxRTN{LkOwOlIh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1355	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnnBTWM2OD1\|Mz6yNFQh\|ryP	NEHvXVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CFPAC-1	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LhVGlEPTB;M{OuNlM{OiEQvF2=	NX7xN3k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MKN28	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3;Se2lEPTB;M{OuN\|gxQSEQvF2=	NUTwVJpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HDLM-2	M4TFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LjUmlEPTB;M{OuOlk{OSEQvF2=	NHuyV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PANC-10-05	M4KzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mmi0TWM2OD1\|ND6xNFE1KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SAS	NEmwb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NE\RO3FKSzVyPUO0MlQ2PjVizszN	NF3yPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC1395	NFf4UINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MW\JR\|UxRTN2LkexPFYh\|ryP	Ml6zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
8305C	M{nrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TObGlEPTB;M{WuPFQyPSEQvF2=	MkfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KM12	M1\2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlz4TWM2OD1\|Nj63OVQ4KM7:TR?=	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1116	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\Y[GlEPTB;M{euOVk6OiEQvF2=	MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	M{PER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkXITWM2OD1\|OD6zN\|g6KM7:TR?=	M2K4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC2218	NEjicVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkDtTWM2OD1\|OD62OVE6KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
T84	NWXVTpdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\4TWM2OD1\|OD63OFA6KM7:TR?=	NWDLZlk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ETK-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX:3d3BjUUN3ME2zPU4xOjJizszN	M3;FTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-800	M1S4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXrJR\|UxRTN7LkO4Olgh\|ryP	NEO5O2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAL-12T	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XYSmlEPTB;M{muOVI5OSEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ACN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYfJR\|UxRTRyLkS5NVEh\|ryP	M{X6clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SJSA-1	NHr1SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGXUV2tKSzVyPUSxMlE2QTZizszN	NX;vVlVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PSN1	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoXFTWM2OD12MT6xO\|Q6KM7:TR?=	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
D-566MG	M2rnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrCPWZKSzVyPUSxMlIxQDZizszN	NVv0NmV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EGI-1	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPPR3YzUUN3ME20Nk41OjhizszN	M4DXO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A204	M1:zPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3TT[GlEPTB;NEKuOlM5QCEQvF2=	M2O0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Saos-2	M3uwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXnYXWxwUUN3ME20Nk45OzZ7IN88US=>	M1W0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SNU-C2B	NHrDR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkjhTWM2OD12Mz62PFc5KM7:TR?=	NYW0XVUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HLE	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETIeHlKSzVyPUS0MlA5PTZizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1463	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NULXVIpQUUN3ME20OE46QTdzIN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DSH1	M4G2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXjJR\|UxRTR3LkCwN\|Mh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MCF7	NXO3Oo1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkLnTWM2OD12NT61NFUyKM7:TR?=	NFvneJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
K5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlfHTWM2OD12NT65OFA2KM7:TR?=	NXL6S2NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H358	NFuyVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYLJR\|UxRTR5LkKxOUDPxE1?	M4LBeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2030	NX\Rc4w3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XhUmlEPTB;NEeuNlM4PCEQvF2=	NWTUTFFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW948	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{[0cWlEPTB;NEeuOFY1KM7:TR?=	M{PIfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BALL-1	NHn2ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWfMNWQ3UUN3ME20O{43OTZ6IN88US=>	NEW0WXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-9	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYf2XXl1UUN3ME20O{46PThzIN88US=>	NHnuUoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-N-FI	M1HqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXvPWhKSzVyPUS4MlA{PThizszN	NUjaUW5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KALS-1	NX3jSZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUjJR\|UxRTR6LkGyPFkh\|ryP	NVXFbmhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	NH3mbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2TuOWlEPTB;NEiuO\|Q1PSEQvF2=	MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2452	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYXJR\|UxRTR7LkGxOVIh\|ryP	M1nMUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OC-314	NF;NTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjCUYdKSzVyPUS5MlY5OzRizszN	M4fQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	4mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04480086	Active not recruiting	Drug: Mivebresib\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	March 17 2021	Phase 1
NCT04454658	Recruiting	Drug: ABBV-744\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	November 11 2020	Phase 1
NCT04041050	Recruiting	Drug: Navitoclax\|Drug: Ruxolitinib\|Drug: Celecoxib	Myeloproliferative Neoplasm	AbbVie	November 8 2019	Phase 1
NCT03181126	Completed	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

定制您的化合物库

Navitoclax (ABT-263)

客户使用Selleck生产的Navitoclax (ABT-263)发表文献272篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品